From: Management of atrial fibrillation in patients taking targeted cancer therapies
Oral Anticoagulants | ||||||
---|---|---|---|---|---|---|
Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | ||
Tyrosine Kinase Inhibitors | Afatinib | |||||
Axitinib | ||||||
Bosutinib | ||||||
Cabozantinib | ||||||
Ceritinib | ↑OAC levels | ↑OAC levels | ↑OAC levels | |||
Crizotinib | ↑OAC levels | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
Dasatinib | ↑OAC levels & effect | ↑OAC effect | ↑OAC levels & effect | ↑OAC levels & effect | ↑OAC effect | |
Erlotinib | ↑OAC levels | |||||
Gefitinib | ↑OAC effect | |||||
Ibrutinib | ↑OAC effect | ↑OAC levels & effect* | ↑OAC levels & effect* | ↑OAC levels & effect* | ↑OAC levels & effect* | |
Imatinib | ↑OAC levels & effect | ↑OAC levels | ↑OAC levels | |||
Lapatinib | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ||
Lenvatinib | ||||||
Nilotinib | ↑OAC levels | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
Osimertinib | ↑OAC levels | ↑OAC levels | ↑OAC levels | |||
Pazopanib | ||||||
Ponatinib | ||||||
Regorafenib | ↑OAC effect | |||||
Ruxolitinib | ||||||
Sorafenib | ↑OAC levels & effect | ↑OAC levels | ||||
Sunitinib | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ||
Vandetanib | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* |